Bionano Genomics (BNGO) Cash from Financing Activities (2017 - 2026)

Bionano Genomics' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $657000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 93.97% year-over-year to $657000.0; the TTM figure through Mar 2026 stood at $13.8 million (down 26.66% YoY), while the FY2025 annual figure was $24.0 million, up 275.66% from the prior year.
• Cash from Financing Activities came in at $657000.0 for Q1 2026 at Bionano Genomics, down from $1.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $68.5 million in Q4 2023 to a low of -$21.6 million in Q1 2024.
• A 5-year average of $8.7 million and a median of $3.9 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 212214.29% in 2023 and tumbled 245.46% in 2024, its largest moves.
• Bionano Genomics' Cash from Financing Activities stood at $146000.0 in 2022, then surged by 46806.85% to $68.5 million in 2023, then sank by 94.32% to $3.9 million in 2024, then plunged by 58.79% to $1.6 million in 2025, then sank by 59.01% to $657000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $657000.0, $1.6 million, and $10.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison